https://alimerasciences.com/products/iluvien-for-diabetic-macular-edema-dme/ https://alimerasciences.com/products/patents/ Diabetic Retinopathy https://alimerasciences.com/areas-of-focus/diabetic-macular-edema-dme/ https://alimerasciences.com/areas-of-focus/retinal-vein-occlusion-rvo/ https://alimerasciences.com/areas-of-focus/age-related-macular-degeneration-amd/
Comprehensive Compliance Program Description
Alimera Sciences, Inc. (Alimera) is committed to conducting its business in compliance with all applicable laws, rules, and regulations and the highest standards of ethical conduct. To this end, we have established and will maintain a Comprehensive Compliance Program (“Compliance Program”) in accordance with the OIG Compliance Program Guidance for Pharmaceutical Manufacturers (the “OIG Guidance”) published by the Office of Inspector General, U.S. Department of Health and Human Services. Our Compliance Program is a key component of our commitment to adhering to the highest standards of corporate responsibility and fostering a culture of compliance that places a premium on doing business with integrity. Our Program also incorporates the Code on Interactions with Healthcare Professionals published by the Pharmaceutical Research and Manufacturers of America.
We have designed our Compliance Program to (1) prevent, detect, and remediate violations of applicable laws, rules, and regulations, as well as Alimera’s policies and procedures and (2) promote a culture of the highest ethics within the company. It is Alimera’s expectation that employees will comply with our Code of Business Conduct and the policies and procedures established in support of that Code. As the OIG Guidance recognizes, however, the implementation of a Compliance Program cannot guarantee the elimination of improper employee conduct.
As recognized in the OIG Guidance, we have tailored our Compliance Program — the fundamental elements of which we have described below – to fit the unique environment of our company. Moreover, our Compliance Program is dynamic and we regularly review and enhance our Program to meet our evolving compliance needs.
You may obtain a copy of this Compliance Program description by calling 1-844-445-8843.
II. Overview of Compliance Program
Compliance Officer. Alimera has appointed a Compliance Officer who is charged with developing, implementing, and monitoring the Compliance Program. We will ensure that the Compliance Officer has the ability to exercise independent judgment and, as necessary, effectuate change within the company. The Compliance Officer reports to the President and Chief Executive Officer of Alimera, is a member of Alimera’s Executive Management team, and has direct access to the Alimera Board of Directors.
Compliance Committee. Alimera has established a Compliance Committee made up of Alimera senior management. The role of the Compliance Committee is to advise and assist the Compliance Officer in the development, implementation, and ongoing oversight of the Compliance Program. The Compliance Committee meets on a regular basis to identify and manage areas of risk and areas of critical focus for the Compliance Program.
Alimera has established written policies and procedures, including our Code of Business Conduct, which articulates our fundamental principles and values and provides a framework for ethical conduct within our company. The Code of Business Conduct establishes our expectation that management, employees, and agents of Alimera act in accordance with all applicable laws, rules, and regulations; Alimera’s policies and procedures; and the highest standards of ethics.
In accordance with California law, Alimera has established an annual spending limit for certain promotional activities directed toward healthcare professionals who prescribe or may influence prescribing in California. At the present time our annual, per-prescriber spending limit is $1,500. Examples of items that fall within this spending limit are occasional modest meals in connection with informational presentations and educational items.
This annual spending limit does not include payments to healthcare professionals for bona fide consulting or other services.
It is Alimera’s policy to not provide any item of value to any healthcare professional with the intent of influencing that healthcare professional’s prescribing habits.
Education and Training
A crucial element of our Compliance Program is the education and training of our employees on their legal and ethical obligations under applicable laws, rules, regulations, and company policies and procedures. Alimera regularly communicates our policies and procedures to promote a thorough understanding of the company’s expectations and regularly reviews and updates our training initiatives.
Internal Lines of Communication
Alimera actively fosters dialogue between management and employees. Our goal is that all employees should know to whom to turn when seeking answers to questions or reporting possible violations of company policies or procedures, and understand that they can make such reports without fear of retaliation. To that end, we have adopted open-door and non-retaliation policies. We have a toll-free compliance helpline to which employees of Alimera may anonymously raise questions or report any concerns or suspected violations of applicable laws, rules, regulations, or Alimera policies or procedures.
Auditing and Monitoring
Alimera’s Compliance Program includes monitoring and auditing to evaluate adherence to Alimera’s policies and procedures.
We note that, in accordance with the OIG Guidance, the nature, extent, and frequency of our compliance monitoring and auditing
may vary according to new regulatory requirements, changes in business practices, and other considerations.
Responding to Potential Violations
When Alimera becomes aware of potential violations of applicable laws, rules, or regulations or company policies or procedures,
the company will promptly investigate such matters and make a determination as to whether the facts substantiate the existence of a violation.
Alimera will document the conduct of such investigations.
Disciplinary and Corrective Action
While each substantiated violation will be considered on a case-by-case basis, where appropriate we will utilize disciplinary action consistent
with company policy to address violative conduct and to deter future violations.
We will also work to determine the root cause of the violation and assess whether the violation is due to gaps in company policies or procedures
and take appropriate corrective action designed to prevent future violations.
III. California Compliance Declaration
Alimera Sciences, Inc. hereby declares that, to the best of our knowledge, information, and belief,
and based upon our good-faith understanding of the statutory requirements, we have, as of March 3, 2015,
established a Comprehensive Compliance Program that is in material compliance with the requirements of California Health and Safety Code §§ 119400-119402.
While Alimera’s Comprehensive Compliance Program cannot completely eliminate the possibility that an individual employee will engage in improper conduct,
our Program is reasonably designed to prevent and detect violations of applicable laws, rules, and regulations, as well as our own internal policies and procedures.
*DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.